Zymeworks Inc. (ZYME)
ZYME trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1937653/000193765326000015/0001937653-26-000015-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | ZYME on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001937653 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $106.0M |
| Net income | -$81.1M |
| Operating income | -$92.5M |
| Net margin | -76.6% |
| Operating margin | -87.3% |
| Revenue growth | +38.9% |
| Cash | $41.2M |
| Total assets | $346.5M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 17.2× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-09 |
| Cash and burn | $100.5M cash; operating cash flow -$28.0M a quarter. | Report 2026-09-30 |
| Shares outstanding | 69,030,691 (2026-11-06); 74,836,534 a year earlier; 70,001,987 three years earlier. | Cover page 2026-11-06 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | KPMG LLP, Vancouver, Canada | PCAOB Form AP 2026-04-06 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $4.7M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $256.5M | $173.7M | -$24.0M | $100.5M | $338.9M | $266.0M | 10-Q 2026-11-09 |
| Q2 2026 2026-06-30 | $4.6M | -$45.0M | -$31.9M | $179.4M | No debt tags | $37.1M | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $2.4M | -$44.2M | -$45.7M | $244.3M | No debt tags | $81.3M | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | $2.5M | -$41.2M | -$10.3M | $41.2M | No debt tags | $106.0M | 10-K 2026-03-02 |
| Q3 2025 2025-09-30 | $27.6M | -$19.6M | -$31.4M | $64.8M | No debt tags | $134.5M | 10-Q 2026-11-09 |
| Q2 2025 2025-06-30 | $48.7M | $2.3M | $12.1M | $98.3M | No debt tags | $122.9M | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $27.1M | -$22.6M | -$3.4M | $76.2M | No debt tags | $93.4M | 10-Q 2026-05-07 |
| Q4 2024 2024-12-31 | $31.0M | -$23.5M | -$41.5M | $66.1M | No debt tags | $76.3M | 10-K 2026-03-02 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2024-08-02 |
| Latest annual report | 10-K | 2026-03-02 |
| Latest quarterly / interim | 10-Q | 2026-11-09 |
| Latest current report | 8-K | 2026-11-16 |
| Latest proxy | DEFA14A | 2026-10-26 |
Source: SEC EDGAR submissions feed, 343 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -11.4% |
| 1 month | +4.7% |
| 3 months | +1.9% |
| Year to date | -0.3% |
| 1 year | +41.8% |
| From 52-week high | -16.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ETON | Eton Pharmaceuticals Inc. | $63.88 | -0.08% | $1.8B |
| AGIO | Agios Pharmaceuticals Inc. | $30.15 | -4.56% | $1.8B |
| ZBIO | Zenas BioPharma Inc. | $27.93 | -0.29% | $1.9B |
| TRVI | Trevi Therapeutics Inc. | $13.29 | -2.64% | $1.9B |
| BRVE | Braveheart Bio Inc. | $19.49 | -0.66% | $1.8B |
| STOK | Stoke Therapeutics Inc. | $26.63 | -0.19% | $1.7B |
| MRVI | Maravai LifeSciences Holdings Inc. | $7.40 | -1.86% | $1.9B |
| HRMY | Harmony Biosciences Holdings Inc. | $32.96 | -2.37% | $1.9B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier